A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia

Trial Profile

A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Gemigliptin/rosuvastatin (Primary) ; Gemigliptin; Rosuvastatin
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms BALANCE
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 13 Jun 2017 Primary endpoint has been met. (LDL-C change rate) as per results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Primary endpoint has been met. (HbA1c change) as per results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top